Paradigm Biopharmaceuticals (ASX:PAR) Long-Term Debt : A$0.18 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Paradigm Biopharmaceuticals Long-Term Debt?

Paradigm Biopharmaceuticals's Long-Term Debt for the quarter that ended in Dec. 2023 was A$0.18 Mil.

Paradigm Biopharmaceuticals's quarterly Long-Term Debt declined from Dec. 2022 (A$0.29 Mil) to Jun. 2023 (A$0.00 Mil) but then increased from Jun. 2023 (A$0.00 Mil) to Dec. 2023 (A$0.18 Mil).

Paradigm Biopharmaceuticals Long-Term Debt Historical Data

The historical data trend for Paradigm Biopharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paradigm Biopharmaceuticals Long-Term Debt Chart

Paradigm Biopharmaceuticals Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Long-Term Debt

Get a 7-Day Free Trial

Paradigm Biopharmaceuticals Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Long-Term Debt	Get a 7-Day Free Trial												0.45	-	0.29	-	0.18

Paradigm Biopharmaceuticals (ASX:PAR) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Paradigm Biopharmaceuticals Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Paradigm Biopharmaceuticals's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Paradigm Biopharmaceuticals (ASX:PAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (ASX:PAR) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

PBIGF:USA

Address

500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000

Website

https://www.paradigmbiopharma.com

Paradigm Biopharmaceuticals Ltd is a biopharmaceutical company that engages in the research and development of therapeutic products for human use in Australia. The firm is engaged in drug repurposing, pentosan polysulphate sodium (PPS) for the lead clinical indication of bone marrow edema, Alphavirus - Ross River virus (RRV) and Chikungunya virus (CHIKV), Mucopolysaccharidosis, and allergic respiratory conditions, including allergic rhinitis (AR) and chronic obstructive pulmonary disease (COPD).